Alliance for Pandemic Preparedness

January 7, 2021

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

Category:

Topic:

Keywords (Tags):

In a randomized, double-blind, placebo-controlled trial of non-hospitalized adults aged ≥75 years (n=160) with mild COVID-19, patients who received convalescent plasma within 72 hours after onset of symptoms were 48% less likely to develop severe respiratory disease than patients receiving placebo (RR = 0.52, 95% CI: 0.29-0.94). Risk of severe disease was 60% lower (RR = 0.40, 95% CI: 0.20-0.81) when patients who developed severe respiratory disease before infusion of treatment or placebo were excluded. 

Libster et al. (Jan 6, 2021). Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2033700